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Introduction
The question of the ethics of drug pricing is a fairly new topic. Discussion started publicly
in March of 2005 when an article in “The Economist” raised questions about many of the
practices that have been going in this industry for years, like overpricing drugs that are no
better than their replacements, and taking that profit to further advertise the products directto-consumer. This discussion has led to a question many Americans ask today: Are these
companies putting profits ahead of people?
What is legally permissible is not always an ethical business practice, especially in the
instance of profiting from healthcare. Law tells an individuals or groups what right(s) they have,
ethics demonstrate the right thing to do. The public has given more focus to the clinical
provision of healthcare than to the business side when considering the ethics of general
healthcare. This is a trend that is beginning to change, as pharmaceutical companies have been
engaging in questionable actions without any repercussions for a long time (Weber 6). The
question this paper looks to answer is, what does an ethical price increase on a pharmaceutical
product look like and can other systems provide us solutions to the issue of high drug prices in
America.

Background
Ethics of a For-Profit Business
It is my position that For-Profit companies have an ethical responsibility to take into
account how their practices, policies, and decisions affect different groups and how to find a
proper balance between the benefits and burdens placed on these groups. A for-profit business
4

is a business that is formed to conduct lawful activities in order to produce a profit for the
owners. Managing a business responsibly requires having a direct relation between ethical
practices and the financial bottom line. Determining the balance between the financial impact a
certain policy or action can have with the “rightness” of that action can be difficult, but is
something that needs consideration in the pharmaceutical industry. This is my position because
a commitment to a high standard of ethics for those affected by a business’s decisions is not
only good for the stakeholders, it is good for the business as well. Weber’s work in this area
suggests companies that will be successful in the future are those that combine a commitment
to profitability with a concrete commitment to the advancement of public interest (15). This
belief, according to Leonard Weber, Simon Webley, and Elise More, means ethics pays. It does
this by encouraging trust in a company, while also improving reputation.
Simply stating “good ethics is good business” undermines the integrity of what it means
to operate ethically, depending on how the phrase is interpreted. W. Michael Hoffman, a
professor of business ethics at Bentley University, has an observation worth considering: “Being
ethical on occasion might require that we place the interest of others ahead of, or at least on
par with, our own interests. And this implies that the ethical thing to do, the morally right thing
to do, may not be in our own self-interest.” (Hoffman 176) This statement suggests good
business is not always good ethics. Good ethics will sometimes lead a business to make a
decision which conflicts with its own immediate interest. This statement provides sufficient
evidence to doubt the phrase “Ethics Pays”, as ethics do not always forward the financial
interest of the business. However, a business will generally have a good public image if it has a
strong commitment to ethical excellence.
5

Stakeholders
Determining whether or not an action is ethical requires an understanding of the parties
involved. In addition to the business there are also the stakeholders. Stakeholders are those
who have something at stake with regard to a company’s products, operations, and/or
outcomes. Stakeholders generally either benefit from or are harmed by corporate activity. They
include both those who voluntarily associate themselves with a certain company and those who
involuntarily feel the effects of corporate decisions.
The pharmaceutical industry involves several key stakeholder groups. Like many
industries, there are the employees, shareholders, and contractors hired by the different
pharmaceutical companies. There are also stakeholder groups that are unique to this industry.
They include the patients that take the products; physicians and other healthcare professionals
that prescribe the medicine; the professionals (clinical researchers, medical educators) that
determine a medicine’s safety, effectiveness, and appropriate usage; those with medical needs
that cannot access the necessary medication; healthcare payers; and those who make decisions
on healthcare policies (Weber 32). The actions that have the greatest impact on these
stakeholders are actions that potentially affect the quality and cost of medical care.
In order to analyze business practices in terms of stakeholder benefits and burdens, I
will be using the Clarkson Principles. These principles, in which the first four of seven directly
apply to pricing in pharmaceuticals, are acceptable to use in this situation because “mutually
satisfactory relationships with a wide range of stakeholders are a critical requirement for
successful corporate operation in the long term” (Donaldson 108). In the context of price
increasing in the pharmaceutical industry, the term manager refers to those who make pricing
6

decisions. These principles are as follows: (1) Managers should acknowledge and actively
monitor the concerns of all legitimate stakeholders, (2) Managers should listen to and openly
communicate with stakeholders about their respective concerns and contributions, (3)
Managers should adopt processes and modes of behavior that are sensitive to the concerns and
capabilities of each stakeholder group, (4) Managers should recognize the interdependence of
efforts and rewards among stakeholders, attempting to equally distribute benefits and burdens
among them (Principles of Stakeholder Management). These Clarkson Principles serve as a
strong core for the responsibilities all companies have toward their stakeholders.
The most important challenge companies’ management faces, and often times the most
difficult, is actively listening to stakeholders. With an industry as large and important as the
pharmaceutical industry, there are a large number of voluntary and involuntary stakeholders.
Actively listening to public interest groups and other activists that express their concerns needs
to be a key role of management. Doing this will educate management on unintended
consequences their policies and actions might have. In this case, good ethics requires good
communication.

Pharmaceutical Patents and Exclusivity
Discussion of the US pharmaceutical industry practices requires an understanding of
how drug patents and exclusivity work and how they can affect pricing dynamics. According to
the FDA, a drug patent is “a property right granted by the United States Patent and Trademark
Office anytime during the development of a drug” (Development & Approval Process (Drugs)).
This patent is valid for 20 years from the date it is filed. New patents can also be filed on the
7

same drug if there is a modification of the drug formula or manufacturing process. Exclusivity is
a way that companies retain monopolistic rights for certain medications. This term refers to
specific delays and prohibitions on approval of competitor drugs available under the statute
that attach upon approval of a drug (Development & Approval Process (Drugs)). The duration of
exclusivity depends on the type of drug, but can range from 3 to 7 years. Since the process of
drug approval can take several years, sometimes drug patents only have a few years left once a
given drug hits the market. Drug exclusivity was designed by the FDA in order to provide
companies with a concrete amount of time to recoup their research and development
investment from a product once approval has occurred.
Drug patents and drug exclusivity apply to given pharmaceutical products in different
ways. One major difference between the two is, the duration of a patent begins on the date of
patent filing, regardless of whether the drug is approved or not. Exclusivity begins once
statutory requirements are met. Interestingly, drugs can have both a patent and exclusivity,
only one of the two, or neither. Also, if a drug has both, these can apply to different aspects of
the drug. According to the U.S. Food and Drug Administration, exclusivity came about as a
means of incentivizing new drug innovation by giving exclusive rights to market and sell a drug,
while also giving the public greater access to drugs through generic competition once the
exclusivity term has expired (Development and Approval Process (Drugs)).

What Determines Price?
An understanding of how drug prices are determined is essential to determining the
ethicality of this pricing. According to Dr. John Virts, an economist for Eli Lilly and Company,
8

there is no such thing as an outright monopoly on drugs within the pharmaceutical industry
(Competitiveness of the Drug Industry 290). He reasons that individual drugs compete with
other drugs in a relatively large therapeutic market, and these larger markets are the ones that
are relevant in economic decision-making. Executives for a company that sell a specific antiinfection drug use the broader anti-infection market to determine its price, as well as
production and research costs (Competitiveness of the Drug Industry 290). Using a broader
market than just a specific medication or product is done to find a possible range of prices.
Companies go further to find the price that will maximize gross return on their product. The
system they use is similar to a trial and error system, where they will find the best combination
of price and volume that attempts to maximize gross return.
According to John E. Calfee, Pharmaceutical companies are able to set their prices high
due to a number of unique factors. The first is the cost structure of pharmaceutical
development. There are high upfront research costs and low marginal costs of manufacturing
and distribution. This allows for new drugs to be sold at a price that far exceeds production
cost, which in turn makes a large gross profit possible (Calfee 38). Another factor allowing for
high pricing is the lengthy time gap between incurring costs from a specific product and
recouping those costs through sales. This allows for those in control of prices to easily ignore
the true cost of the product. A third factor is the unique nature of the products pharmaceutical
companies are trying to produce. The result of research is often a single chemical entity that
cures disease, while thousands of similar molecules do nothing or make the existing condition
worse. The information on this single chemical entity is the only thing that is valuable, and once
revealed, any non-research firm can produce it as a generic (non-patent) drug (Calfee 38).
9

These factors can be seen in many different examples of pharmaceutical products and the
setting of their price.
AZT, or azidothymide, is one of the most referred to examples of a drug with a
seemingly excessive price. AZT is an effective medicine used for treating HIV and the
complications that arise from AIDS, often times making it a life-saving medicine. The price for
this drug can cost as much as $6500 per dose for a single patient, a price that is viewed as
unethical by many AIDS patients, especially those without insurance coverage (Spinello 617).
Industry observers have come to the conclusion that the company that sells this drug,
Burroughs-Wellcome, came to this price by making it about as expensive as high-end cancer
therapy medicines (Spinello 617). This idea is in line with Dr. John Virts conclusion that
companies use a relatively large therapeutic market. This company used the larger market of
cancer therapy to determine the price of their AIDS medicine. Burroughs-Wellcome has
justified the high price saying the drug had cost them a great amount of money to develop.
They also maintain that they priced this drug so high due to fear of it becoming obsolete at any
given moment. A second generation of AZT developed by a different company would wipe out
the need for the Burroughs-Wellcome version. Also, as soon as their patent expires, generic
competition will come in and drive down the market price for this medication. This raises
concerns about companies setting unfair prices simply because they feel the need to generate
as much profit as they can while they have control of the drug’s market share (Spinello 618).

10

Dermatological and Specialty Drug Pricing and their Pricing Models
Dermatological Pricing as an Example of Increasing Price
One sector of medicine that has seen significant price increases over the past seven
years is dermatology. Miranda and Steven P. Rosenberg performed a study on the rise in price
of 19 different dermatological products from 2009-2015. They found that the average mean
increase in price for all acne and rosacea medicines was just under 200% over the six year
period. Also, of the 19 name-brand drugs’ prices recorded, four quadrupled in price (M.
Rosenberg, S. Rosenberg 160). New medication introduced to the market tends to be more
expensive due to research, development, and costs associated with FDA approval. Many of the
drugs surveyed, however, have been available for 10 years and have generic options available.
These drugs were among those with the highest increases in pricing (M. Rosenberg, S.
Rosenberg 161). The Rosenbergs also found that there were 2 medications on the drug
shortage list, naturally causing the price to increase. However, both drugs have since been
taken off the shortage list, and the prices still continued to grow.
The Rosenbergs came to the conclusion that the price of name-brand and generic
dermatological drugs has increased significantly since 2009. Multiple, frequently prescribed
drugs have gone through price increases that greatly outpace inflation, the overall growth of
GDP, and the increase of reimbursement for physician services (M. Rosenberg, S. Rosenberg
162). For example, Benzacilin, a frequently prescribed acne medication experienced an increase
of 202% over the 7 year span, effectively doubling in price. This is a modest example from those
medications surveyed. Targretin gel experienced a massive increase in price. A single dose cost
$1686 in 2009, and $30,320 in 2015. This is a price increase of almost 1700%.
11

Fig 1:“Changes in Retail Prices of Prescription Dermatologic Drugs from 2009 to 2015”
(M. Rosenberg, S. Rosenberg 161)

Specialty Drugs
Specialty drugs are a sector of pharmaceuticals that are expensive and chemically
complex, and have been experiencing a dramatic increase in price since 2011. Often used for
treating rare or complex conditions like cancer or rheumatoid arthritis, these drugs come in the
form of a biologic, meaning according to the U.S. Food and Drug Administration a medication
that was derived from a human, plant, or microorganism cell ("What Are 'Biologics' Questions
and Answers.") Typically, generics do not need to go through extensive testing to obtain
“bioequivalence” with its name-brand counterpart. This is not the case for biologics. According
to a biologics industry website, due to the complexity of biologics, it is too difficult for a
secondhand manufacturer to create a product that will pass as therapeutically equivalent
(“How Do Drugs and Biologics Differ?”). The complexity greatly reduces the competition for
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these specialty products, allowing for drug companies to raise the price of already expensive
specialty drugs. The size of the specialty drug sector in reference to the number of products is
growing as well (Dvorin).
The specialty drug sector of pharmaceuticals has grown both in therapeutic categories
and big money products. For the first time ever, the FDA approved more specialty drugs than
conventional drugs in 2010 (Dvorin). This has been a trend that has repeated through 2015 as
well. The CVS Caremark specialty drug list contains more than 400 different specialty products
that span 50 therapeutic categories (Dvorin). The sheer number of drugs is not the only thing
that has seen a major increase, the price is going up as well.
Specialty drugs are experiencing an increase in percent of overall pharmaceutical
spending by Americans, even though specialty drugs are not widely taken. It is estimated that In
2015, between 1 and 2 percent of Americans were on some sort of specialty medication, but
these products make up about 38% of drug spending in America ("Specialty Drugs and
Healthcare Costs”). These drugs are expensive, and continue to rise in price. According to
Express Scripts, the largest pharmacy benefit management company in the US, specialty drugs
experienced a 25.2% increase in price in commercial plans, and a 34.3% increase in price for
Medicare plans. This statistic suggests pharmaceutical companies are exploiting governmental
healthcare plans, in turn deflecting the increase in price to the taxpayers. Conversely,
conventional drugs experienced a 6.5% increase in price for private medical plans and 5.9%
increase in price for Medicare plans (Dvorin). The increase in price of specialty drugs far
outpaces that of conventional medicines. The demand for specialty medicine has also gone up.
CVS reported specialty drug utilization went up 5.7% in 2014, compared to just 1.4% for
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conventional drugs (Dvorin). This pricing is due to increased use of existing specialty
medication, as well as the introduction of new specialty pharmaceuticals that have little to no
competition that would potentially bring the price of these new products down.
Medicaid provides the national average drug acquisition costs for thousands of
medications, and the data there supports the notion that specialty drugs are increasing. Stelara,
a drug used to treat plaque psoriasis, was priced at approximately $12,900 per dose in 2012.
Today, it costs about $18,300 per dose. Over the course of a year, this medication can cost
upwards of $110,000, as this medication is injected about 6 times per year. That means Stelara
now costs patients, on average, about $33,000 more per year (“NADAC Comparison”).
Depending on the individual’s insurance plan, some or all of the extra costs may not be
covered, requiring more out of pocket costs for the consumer. 1
Another example of a specialty medication that has shown a dramatic increase in price
is Simponi Aria, a specialty medication used to treat rheumatoid arthritis. It increased from
approx. $5,000 per dose in 2013 to just under $8,000 per dose today. This is medication that is
administered between 8 and 9 times per year, bringing the yearly cost up to $68,000, when it
was $42,500 just 4 years ago (“NADAC Comparison”). These medications are expensive and are
experiencing constant price increases.

1

For example, Stelara is not a life-saving product, and thus it is fully covered for Medicaid users
in only 10 states (“Insurance Coverage”). This leads to high out of pocket costs.
14

Justification for Price Increasing
Looking at the pricing tactics of companies and comparing these prices with their
rationales shows whether or not there is ethical consistency. The financial data of the company
will be examined to determine which stakeholders are, or have been, receiving benefits,
whether these are sufficient. Several types of financial data come under consideration. This
includes publicized accounts of rationale behind price increases, percentage of revenue
dedicated to research and development, dividend payments to shareholders, as well as sales,
general, and administrative costs. The first step in this ethical analysis is determining the ethical
defense used by drug executives, especially Turing and Valeant, as their price increases have
been widely discussed by the public.

Valeant
I will begin my examination of drug pricing by looking at the case of Valeant. The two
major products they have increased in price were Nitropress and Isuprel back in 2015, along
with others. As with Daraprim, these medications were not developed by Valeant, the patents
were bought from other companies. Valeant has faced harsh criticisms for acquiring patents of
pharmaceutical products from rival companies, then increasing the price of these products
drastically.
Valeant has several defenses for the ethical claims against their practices. Valeant is the
largest medical provider for dermatology outside of biotech medicines, so they believe it is
natural to have a few drugs on the price increase list. Secondly, Valeant claims that the retail
price does not represent the price that insurers and patients are paying for their products, as
15

they offer financial assistance to a majority of their patients by Valeant themselves in the form
of subsidies, determined on a case by case basis. Hospitals rarely pay the full price tag to carry
their products, and depending on how much of this medication they buy, hospitals can get up
to a 40% rebate ("Valeant Comments on Discount and Rebate Program for Nitropress and
Isuprel”). Thirdly, four of their five drugs from the study have generics available, meaning a
patient does not have to choose their product (Pollack). The price of generics has seen its fair
share of price increases. Since 2009, some generic dermatological medicines have quadrupled
in price (M. Rosenberg, S. Rosenberg 161). This is not the case for generics to Nitropress,
however, as a generic product recently approved that threatens the market share of Nitropress
greatly.
Other than the justifications just described, Valeant gives some vague explanation for
their pricing tactics. Valeant claims these prices are determined by clinical benefits, as well as
the value these products bring to patients, physicians, payers, and society (“Pharma CEO
Admits: Our Business is Profit, Not Helping Sick People”). Increase in price is also directly
related to concern over generic competition once their exclusivity rights expire. J Michael
Pearson, the former CEO of Valeant, said this: “If products are sort of mispriced and there exists
an opportunity, we will act appropriately in terms of what I assume our shareholders would like
us to do.” (“Pharma CEO Admits: Our Business is Profit, Not Helping Sick People”). This shows a
prioritization of one stakeholder group over others when making the decision to increase on
price.
The financial data of Valeant supports the notion of unethical business practice. Their
R&D as a percent of revenue has been between 3% and 4% for the past 4 years, when the
16

average of the top 15 pharmaceutical companies by revenue for R&D expenditures has been
around 16%-17%. Valeant carries a large amount of debt, however, so taking money away from
R&D and repaying that debt is sensible. Valeant has not paid a dividend to shareholders since
2010, presumably because they have only had a positive net income twice since then. However,
when they were paying a dividend, the percent of revenue that went toward that figure
averaged about 27% percent over a four year span, when the industry average of companies
that paid a dividend over that same time span was about 9.5%. The current CEO of Valeant,
Joseph Papa, made about 63 million in 2016 (Egan). The majority of this salary comes in the
form of stock options, and is well over what Merck’s CEO made in 2015 (approx. $25 million)
and what Johnson and Johnson’s CEO made in 2014 (approx. $24 million). This shows a pattern
of Valeant prioritizing shareholders and executive salaries above all other stakeholders in their
pharmaceutical operations.
Although Valeant’s increases of price are widely seen as unethical, it may be the
byproduct of a larger issue, that being a demanding regulatory environment. The cost to
research and develop new pharmaceutical products in the US is very high, creating a large
barrier to entry for competitors. A solution that could eliminate these problems is to make it
easier and less expensive for companies to bring competitors to the market (Thomas).

Turing
Turing was the company responsible for the massive price increase of the HIV drug
Daraprim. This drug was not developed by Turing. The patent was acquired from another
company. The price of this drug went from $13.50 per unit to $750 in August of 2015. This
17

decision caused controversy, and the ethics revolving around this price increase were not
smooth initially.
Turing executives have made statements that they did not follow through with.
According to emails sent among Turing executives, company officials were ecstatic about the
Daraprim patent acquisition, thinking it would make them a fortune knowing they would raise
the price. In company emails sent among officials, this statement was made: “As long as
everyone who needs Daraprim can get it as soon as they need it, regardless of ability to pay, the
community should have no issue.” (Kodjak) Patients getting this medication as soon as they
needed it did not happen. An uninsured patient was not able to acquire Daraprim for over a
week at Massachusetts General Hospital, and such cases prompted many doctors to speak out
against the decision to raise the price so high (Kodjak). This then led Turing to take further
action, as it was necessary for the company to follow through on its promise to get this
medication promptly to all who need it.
Company Officials made specific statements that regard shareholders of his company
above any other stakeholder. In emails sent between company officials, celebrations were
made when they acquired the drug knowing they were going to bring up the price an
astronomical amount. Company chairman Ron Tilles had this to say: "Very good. Nice work as
usual. $1bn here we come." (Kodjak) Knowing this specific product did not have a large market
then saying this shows money comes before advancements, affordability, and access. Shkreli
has also made statements putting money and shareholders above all else. When asked what he
would do if he could go back and do things differently, he has this to say: “I could have raised
Daraprim higher and made more profits for our shareholders. Which is my primary duty."
18

(Baldelomar) One could argue maximizing profits for shareholders is not the primary duty of a
CEO. Ezekial J Emanuel, MD, PhD, chair of the department of medical ethics and health policy at
the University of Pennsylvania, states that pharmaceutical companies need to price their
products responsibly while getting a fair return. Other industries have returns that are a
fraction of the pharmaceutical industry, yet still make good profits and returns for their
investors (Baldelomar).
Turing suffered financially from the price increase of Daraprim. As a company, Turing
posted a 14.6 million dollar net loss in the 3rd quarter of 2015, which is the quarter in which
they acquired Daraprim (Ramsey). This big of a loss shows that raising the price of this drug
damaged the financial well-being of Turing, in addition to their public image being tainted. It
also indicates that even though Shkreli showed the most concern for the company’s
shareholders when deciding to raise the price, they suffered as well.
The financial data for Turing, as well as press releases, show the adjustments made after
the initial criticisms. Turing dedicated 60% of their net revenue in 2015 to research and
development of better toxoplasmosis medications, which is what Daraprim is used to treat
(“Research and Development”). Additionally, Turing has cut costs 50% since the initial price hike
to $750 per unit, making the medication more affordable so hospitals can carry their product
more readily. Another action Turing has taken since the initial price increase is to make this
medication extremely inexpensive for patients on Medicaid. If an individual is on Medicaid or a
state funded health insurance, one bottle of pills will only cost a dollar. Two-thirds of the sales
for Daraprim are of this nature ("Turing Reduces Cost of Daraprim"). These adjustments show
Turing did a fair job of actively listening to the stakeholders involved with Daraprim, and
19

decided to take action to reduce damage to those who were bearing the greatest burdens. This
shows a regard for all Clarkson Principles previously discussed.

Foreign Policy Review
After conducting a review of several different international pharmaceutical markets, I
would like to discuss a variety of policies and procedures being used by other countries in order
to control medical pricing. The markets I reviewed all come from European countries, with a
variety of social approaches to healthcare systems. The first possible solution comes from the
German Market.
The German pharmaceutical market is similar to the US market in relation to other
European countries in terms of pricing. Up until 2011, companies were free to set prices at
whatever level they would like, with the ability to raise those prices as well. The result of this,
were prices that were about 26% higher than the EU average (Sieler et al, 23). The German
government acted, as they were facing a large deficit from the state’s statutory insurance
system. One of the results of their actions was a law called the ArzneimittelmarktNeuordnungsgesetz (AMNOG). This law requires companies to prove that new products are
clinically more effective than previous products on the market. These truly innovative products
have the privilege of unlimited reimbursement from the state’s healthcare and private insurers
(Elhewaihi). The German government does not rate the innovation of a product on a binary
system of innovative or not innovative; they use a scale ranging from 1-6, which then
determines how much of the cost will be reimbursed by the government. Products that are not
seen as clinically more effective than similar products on the market are given a reference
20

price, which is the maximum price the German government will cover. If the price of
medication is greater than the reference price, the patient must pay the difference or turn to a
generic (Elhewaihi). The intention of AMNOG was to reduce the price of drugs that are trying to
become competitors but are also trying to hide under the guise of being innovative, when there
is no proven therapeutic advantage to the product. AMNOG has been credited with lowering
the government’s overall pharmaceutical bill, while also dropping the reimbursement price of
new drugs below the EU average (Sieler et al, 23).
Switzerland has also created an effective pharmaceuticals market that operates in
similarly to the United States system with regard to price regulation. The Swiss government
does not set a cap on how high a drug can be priced. That is determined by the manufacturer.
There is an exception to this rule, however, and that is if the Swiss government has placed a
given drug on its reimbursement list, called the “Positive List” (Paris, Docteur 12). The Swiss
Federal Office of Public Health regulates inclusion to the reimbursement list and the maximum
price a given drug can be while on that list. The Swiss government uses specific criteria to
determine if a drug should be included. For example, the drug must be proven effective based
on controlled clinical trials. The drug must also be a good value for its price. This is determined
by looking at the drugs’ price in other markets, as well as by looking at how effective the drug is
compared to its closest competitor. For products that are included on the positive list, the
government regulates every step of business. They control the cost to manufacture,
distribution margins, and payments for pharmacists’ services (Paris, Docteur 12). If a company
does not wish to have a drug included on this list, they are free to price their products at any
level, but will not receive any state reimbursement. All regulation is done by the Swiss Federal
21

Office of Public Health, or OFSP. Along with OFSP regulation, prices are also subject to
investigation from the Price Council, an independent authority in charge of protecting the
consumer from excessive prices resulting from companies that are in a monopolistic position
(Paris, Docteur 12). The Price Council monitors products not included on the positive list as well.
They educate the general public through frequent reports, comparing drug prices to prices in
other markets nearby, equipping the consumer with the proper knowledge in order to make an
informed decision.
The French system of pharmaceuticals is another example of a foreign market that has
more affordable pricing than the US. French citizens are almost all covered (99% of population)
by statutory state health insurance (Chicoye, Chhabra). The reimbursement system is similar to
the Swiss positive list, in which the government determines whether or not a product will be
reimbursed. There is one difference, and that is the French government does not regulate the
price without negotiation. The French Health Products Pricing Committee and drug companies
sign a number of contractual agreements, which give the state funded health system a variety
of flexible means to monitor prices and drug use (Sauvage).
The French government bases drug approval on five different criteria: efficacy and
safety, position of the medicine in the therapeutic strategy and the existence or absence of
therapeutic alternatives, severity of the disease, type of treatment (preventive, curative or
symptomatic), and public health impact (Chicoye, Chhabra). The evaluation is then placed into 5
different categories, ranging from majorly important, important, moderately important, weak,
and insufficient. The percent of the pharmaceutical product cost to be reimbursed by the
government is then determined. About 76% of pharmaceutical products were reimbursed by
22

the French government in 2007 (Chicoye, Chhabra). In that same year, the French government
approved 92% as moderately important or better. Drugs recognized like irreplaceable and
particularly expensive are reimbursable at 100%. Also, those inflicted with certified chronic
illnesses are reimbursed for 100% of the cost of pharmaceutical products, regardless of the
reimbursement rate for other patients who may use those products for other reasons (Chicoye,
Chhabra).

Ethical Conclusion
Now that I have examined a variety of European models, I would like to consider what
effects other systems might have on the ethical problems thus far discussed. Using the
Europeans models of pharmaceuticals previously discussed, several ethical issues faced by
Turing could be eliminated. Since Daraprim is a life-saving drug for those who are affected by
toxoplasmosis, it would likely be included on the list of reimbursed products, as it is life-saving.
In the Swiss model, companies get to choose if they want to include their product on the
reimbursement list. Giving Turing the choice to include their product on the list would show
whether they are more concerned with making sure their product is readily available to all who
need it or making as much money as they can by setting the price higher than what the
government wants their product priced at. Applying the French model to the Daraprim pricing
dilemma would also solve the ethical pricing issue. Since this is a drug mostly for HIV patients, it
would be reimbursed by the government 100% to the patient. Also, allowing Turing to
negotiate a fair market price with the government for those who may not use it for HIV
complications would ensure all are acquiring the product for a fair price. Germany’s AMNOG
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would make certain the new and improved Daraprim being developed by Turing currently is
truly effective. Doing this would eliminate Turing using a high R&D budget and intentions to
develop a better drug as a disguise to increase the price with intentions of the board members
to get wealthy.
I believe the most effective foreign system elements that would aid the US in becoming
more ethical in terms of pricing comes from France. The US should implement their system of
agreeing upon a price for a pharmaceutical product when it is introduced to the market. This
allows for companies to make the money they need in order to advance their business, as well
as keeping prices reasonable for patients who need medication. Also, having the government
cover all costs for those who deal with chronic illnesses is something that should be considered.
Paying for necessary medication over several years is a massive financial burden for US
patients. Covering their costs and contracting pharmaceutical pricing would make the US
pharmaceutical system more ethical.
Another element that would could work for the US is Germany’s AMNOG law. This has
been a very effective element of Germany’s pharmaceutical system in recent years, bringing
them from one of the higher spending countries in Europe on pharmaceuticals to an average
country in terms of drug expenditures. AMNOG has shown the proof of innovation in new
products will bring down the overall price, as non-innovative products do not get to hide under
the disguise as being innovative. I believe a law like this would be extremely useful in the
United States.
With regard to an analysis of the behavior of the two companies cited, it is my opinion
that neither fully lived up to the utilitarian ideals that they seemed to claim to promote. In
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looking at the example of Turing, I must conclude that they failed to live up to the Utilitarian
model that they seem to be promoting. Great priority was given to the shareholders of the
companies over all other stakeholders, and the great losses Turing posted in the quarter that
contained the price increase shows the company lost a significant amount of money. For those
stakeholders who were disregarded, for example the patients, Turing faced a massive amount
of criticism before accommodations were made to make Daraprim more readily available. The
adjustments made do show active listening, but too many negatives occurred for these
adjustments to make up for the damages. All things considered, the price increase of Daraprim
was unethical.
The ethics involved with Valeant’s decisions to increase the price on several of their
products can be seen as questionable. The quote from the former CEO shows a disregard for
any stakeholder other than those with financial investment in their company. Financial burden
on patients and insurance companies does not seem to be considered in their pricing tactics, as
it has not been shown that they give any consideration for those on any government funded
health insurance. Valeant prioritizes a group of stakeholders (shareholders), they don’t come
close to contributing to the average R&D expenditure of the pharmaceutical industry, and they
compensate their CEO such a large sum of money when their financial statements in recent
years show they have not performed to what they are paying him. However, these price
increases could some understanding, as I feel it could’ve been a way to keep the company from
folding, as they have performed poor financially since 2012.
All price increases I’ve investigated were perfectly legal under US law, but I have found
several to be unethical. To raise the price of a pharmaceutical product ethically, there are
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several elements that need to be present. The first element attempting to equally distribute
benefits and burdens among the stakeholders when making the decision. Often, companies
increase prices and justify it in terms of making money for their shareholders. Second,
companies need to make accommodations in order for all people who need the products to
have access to them. Turing did this, but only after they were criticized by media, the public,
and politicians alike. Lastly, companies need to set aside more money into research and
development. Advancement of the pharmaceutical field in terms of new discovery should be a
higher priority for all drug companies.
After collecting data on pharmaceutical prices in the US compared to other countries, I
believe it is important for the US to find a way to stop pharmaceutical companies from having
the opportunity to raise the price of their products without a limit for the sake of their
shareholders. It has been shown that the burdens of increasing price are often unfairly
distributed to other stakeholders, like hospitals, the patient, and insurance companies.
Referring to foreign pharmaceutical markets like France, Germany, and Switzerland provides
the United States with solutions to the high price problems faced, such as affordability for the
patient. Actively listening to stakeholder issues and abiding by the Clarkson Principles in our
current system is how a given pharmaceutical company can operate most ethically when
making pricing decisions, such as when to increase the price of a product and by what amount.
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Appendix A
Data on Various Pharmaceutical Products
(PPU = Price per Unit)

("NADAC Comparison.") ("> 300 Percent Change.")
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Appendix B
Financial Data of Top 15 Global Pharmaceutical Companies by Revenue
(All figures represented are in millions. Adjusted to US dollar using average annual exchange rate)
(TTM = Trending Twelve Months)

Johnson & Johnson

("Johnson & Johnson: Financials.")

Roche

("Roche Holding AG ADR: Financials.")

Pfizer

("Pfizer Inc: Financials.")
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Novartis

("Novartis AG ADR: Financials.")

Bayer

("Bayer AG ADR: Financials.")

GlaxoSmithKline

("GlaxoSmithKline: Financials.")
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Sanofi

("Sanofi SA ADR: Financials.")

Merck

("Merck & Co Inc: Financials.")

AbbVie

("AbbVie Inc: Financials.")
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Gilead

("Gilead Sciences Inc: Financials.")

Teva

("Teva Pharmaceutical Industries Ltd ADR: Financials.")

Amgen

("Amgen Inc: Financials.")

AstraZeneca

("AstraZeneca PLC ADR: Financials.")
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Eli Lilly

("Eli Lilly & Co: Financials.")

Bristol-Myers Squibb

("Bristol-Myers Squibb Company: Financials.")

Averages
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Appendix C
Valeant Pharmaceuticals Financial Data
(All figures represented are in millions. Adjusted to US dollar using average annual exchange rate)
(TTM = Trending Twelve Months)

("Valeant Pharmaceuticals International Inc: Financials.")
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